Arbitel 80 mg Tablet (Telmisartan 80 mg) – ACI Limited

1. About Arbitel 80 mg Tablet (Telmisartan)

Arbitel 80 mg Tablet contains Telmisartan 80 mg, an Angiotensin II Receptor Blocker (ARB) for hypertension, cardiovascular risk reduction, and diabetic renoprotection, manufactured by ACI Limited, Bangladesh. Telmisartan 80 mg is the target maintenance dose for patients with moderate-to-severe hypertension or established cardiovascular disease requiring maximal ARB effect. It provides the most potent blood pressure reduction among telmisartan doses, with once-daily convenience backed by a uniquely long 24-hour half-life that ensures smooth, sustained antihypertensive action throughout the day.

As an ARB, telmisartan is particularly suited for diabetic and CKD patients — providing RAAS-mediated renal protection, reduction in proteinuria, and no ACE-inhibitor-associated cough. In clinical practice, Arbitel 80 mg is used as the titrated target dose when 40 mg is insufficient, or as initial therapy in patients with moderate-severe hypertension and high cardiovascular risk requiring prompt BP control.

2. Mechanism of Action

Telmisartan acts as a highly selective, long-acting AT1 receptor blocker. Its high AT1/AT2 selectivity ratio (~3,000:1) ensures specific blockade of harmful angiotensin II effects — vasoconstriction, sodium/water retention via aldosterone, and organ remodelling — while allowing beneficial AT2-mediated vasodilation and tissue repair. The insurmountable (non-competitive) binding kinetics of telmisartan contribute to prolonged receptor occupancy beyond its plasma half-life, explaining the 24-hour duration of effect. PPAR-γ partial agonism at therapeutic doses contributes additional metabolic benefits, particularly relevant in diabetic hypertensive patients.

3. Indications

• Hypertension: Maintenance/target dose after initiation and titration from lower doses
• Cardiovascular risk reduction: Evidence-based 80 mg dose from ONTARGET trial
• Type 2 Diabetic Nephropathy: Proteinuria reduction, CKD progression slowing
• Left ventricular hypertrophy regression
• Combination antihypertensive backbone: With Amlodipine (Arbitel AM 5+80) or HCT (Arbitel Plus 80+12.5)

4. Dosage and Administration

Standard: 80 mg once daily. Starting dose for most patients is 40 mg; titrate to 80 mg after 4–8 weeks if BP not at target. Maximum 80 mg/day.

Volume-depleted/elderly: Start at 20–40 mg. Titrate up once volume status and tolerance confirmed.

Hepatic impairment (mild-moderate): Max 40 mg/day. Contraindicated if severe.

Take once daily at consistent time, with or without food.

5. Contraindications

• Hypersensitivity to telmisartan
• Pregnancy (all trimesters — teratogenic/fetotoxic)
• Severe hepatic impairment or biliary obstruction
• Combination with aliskiren in diabetes or eGFR <60 ml/min

6. Warnings and Precautions

Pregnancy: Strictly contraindicated. RAAS blockers cause oligohydramnios, foetal renal dysplasia, and neonatal death. Stop immediately on pregnancy confirmation — switch to safe alternative.

Hypotension: Volume depletion increases first-dose hypotension risk. Correct volume depletion; initiate at lower dose. At 80 mg, more pronounced BP reduction — monitor in elderly and those on concomitant antihypertensives.

Renal function/hyperkalaemia: Monitor creatinine and K+ in CKD and diabetes. Discontinue if bilateral renal artery stenosis diagnosed.

Hepatic impairment: Biliary clearance pathway. Max 40 mg in hepatic disease.

7. Side Effects

Common: Dizziness, fatigue, headache, back pain, diarrhoea, URTI.

Uncommon: Orthostatic hypotension, hyperkalaemia, elevated creatinine, sinusitis, anaemia.

Rare: Angioedema, hepatic dysfunction, thrombocytopenia, myalgia.

Not expected: Dry cough — unlike ACE inhibitors, telmisartan does not raise bradykinin. Cough-free antihypertensive option.

8. Drug Interactions

• Antihypertensives/diuretics: Enhanced BP lowering — monitor, start titrated
• NSAIDs: Reduce antihypertensive effect; increase renal impairment risk
• Digoxin: Telmisartan raises digoxin Cmax ~50% — monitor digoxin levels
• Lithium: Raises lithium levels — monitor toxicity
• K+-sparing agents: Additive hyperkalaemia risk
• Dual RAAS (ACE inhibitor/aliskiren): Contraindicated in diabetic CKD — no additional benefit, excess harm per ONTARGET/ALTITUDE

9. Pharmacokinetics

Bioavailability: ~58% at 80 mg. Tmax: 0.5–1h. Protein binding: >99.5%. Hepatic glucuronidation; >97% biliary/faecal excretion. t½: 24h — longest among ARBs. No active metabolites. No dose adjustment in renal impairment. Bioavailability reduced in hepatic impairment — cap 40 mg/day.

10. Choosing Between Arbitel 40 and 80 mg

Arbitel 40 mg is the standard starting and initial maintenance dose for most hypertensive adults. Arbitel 80 mg is appropriate when: BP remains above target (>140/90 mmHg or >130/80 in T2DM) on 40 mg after 4–8 weeks; the patient has established cardiovascular disease or T2DM with end-organ damage requiring maximal ONTARGET-dose protection; or when maximum renoprotective effect is needed in diabetic nephropathy with significant proteinuria. Always titrate gradually — start 40 mg, assess response, then escalate to 80 mg.

11. Telmisartan vs Other ARBs at Maximum Dose

At maximum doses: telmisartan 80 mg provides antihypertensive effect comparable to valsartan 160–320 mg and olmesartan 40 mg, but with superior duration of action (24h vs 13h for valsartan). Compared to losartan 100 mg, telmisartan 80 mg is more effective in head-to-head trials, providing greater BP reduction and more consistent 24-hour control. The ONTARGET trial is unique to telmisartan — no other ARB has this level of cardiovascular outcome evidence at its maximum dose. For patients with both hypertension and high CV risk (T2DM, established CAD), telmisartan 80 mg is the evidence-based ARB choice.

12. ACI Limited Arbitel Range

ACI’s complete Arbitel range: 20 mg (initiation), 40 mg (standard starting), 80 mg (target/CV risk dose), AM 5+40/5+80 (ARB + CCB), Plus 40+12.5/80+12.5 (ARB + thiazide). All telmisartan strengths and combinations available from a single trusted Bangladesh manufacturer.

13. Storage

• Below 30°C, cool, dry, protected from moisture
• Original blister. Keep from children.
• Do not use after expiry.

Frequently Asked Questions (FAQ)

Q1: What is Arbitel 80 mg (Telmisartan) used for?

Arbitel 80 mg is prescribed for hypertension requiring maximum ARB dose, cardiovascular risk reduction in high-risk patients (CAD, stroke, T2DM with end-organ damage), and maximum renoprotection in diabetic nephropathy. The ONTARGET trial established 80 mg as the evidence-based dose for reducing heart attacks, strokes, and cardiovascular death — matching ramipril (ACE inhibitor) effectiveness but without causing cough. It is also used as the backbone of combination antihypertensive regimens (+ amlodipine: Arbitel AM 5+80; + HCT: Arbitel Plus 80+12.5).

Q2: When should I be upgraded from Arbitel 40 mg to 80 mg?

Your doctor will consider upgrading to Arbitel 80 mg if blood pressure remains above target (>140/90 mmHg general, or >130/80 mmHg if you have diabetes or kidney disease) after 4–8 weeks on 40 mg. Patients with established cardiovascular disease, T2DM with significant albuminuria/proteinuria, or those at very high cardiovascular risk may be started on 80 mg directly or escalated quickly. Do not self-adjust the dose — your physician will assess the benefit-risk balance and monitor your blood pressure, kidney function, and potassium before and after dose escalation.

Q3: Does Telmisartan 80 mg protect the kidneys in diabetes?

Yes — telmisartan 80 mg provides significant renoprotection in T2DM. By reducing efferent arteriolar pressure in the kidney’s glomeruli, it decreases proteinuria and slows the rate of GFR decline in diabetic nephropathy. In the DETAIL trial, telmisartan 80 mg showed renoprotective effects comparable to enalapril (ACE inhibitor) in diabetic nephropathy patients over 5 years — with similar reduction in GFR decline and proteinuria. No dose adjustment is required even in severe CKD (biliary elimination), making it one of the few antihypertensives safe across all stages of diabetic kidney disease.

Q4: Can Arbitel 80 mg be taken alongside diabetes medications?

Yes — telmisartan is compatible with all common diabetes medications including metformin, sulphonylureas, DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1 agonists, and insulin. Telmisartan’s PPAR-γ partial agonism at 80 mg may even contribute to modest improvement in insulin sensitivity. However, monitor blood pressure carefully when combining ARBs with SGLT-2 inhibitors (both lower BP and can cause volume depletion) to avoid excessive hypotension. Regular monitoring of renal function and potassium is recommended for all diabetic patients on telmisartan.